Skip to main
NYXH

Nyxoah SA (NYXH) Stock Forecast & Price Target

Nyxoah SA (NYXH) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 0%
Buy 67%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Nyxoah is a health-technology company with a positive outlook due to several key factors: a successful US launch with strong Q2 results and the addition of 15 new sales reps, a software upgrade for their Genio system that will track sleep quality and compliance, progress towards FDA approval for a new indication, and a planned pursuit of a new CPT code for reimbursement. In addition, the company has introduced revenue guidance for FY26 above street expectations and has multiple pathways for future growth, including a pending catalyst with the results of their ACCCESS trial. This, combined with the positive data points and increased sales force, leads to an optimistic 2026 outlook with potential for increased market share and revenue.

Bears say

Nyxoah is showing strong revenue growth at +499% y/y and +13% q/q in Q1, but its gross margin and opex spend were below estimates, indicating potential issues with profitability. The company also faces standard adoption risks as it competes against market leader Inspire Medical Systems and must obtain additional capital to sustain its cash-burn-heavy business. There is potential for regulatory risks as the company awaits completion of its ACCCESS study, which is a key catalyst for further success.

Nyxoah SA (NYXH) has been analyzed by 3 analysts, with a consensus rating of Buy. 0% of analysts recommend a Strong Buy, 67% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Nyxoah SA and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Nyxoah SA (NYXH) Forecast

Analysts have given Nyxoah SA (NYXH) a Buy based on their latest research and market trends.

According to 3 analysts, Nyxoah SA (NYXH) has a Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Nyxoah SA (NYXH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.